english          中文

Palliative Care

The following Palliative Care studies are now recruiting in Nottinghamshire Healthcare NHS Foundation Trust.

PiPS2 : The Prognosis in Palliative care Study II

Principal Investigator: Dr Alpna Chauhan

Study Summary: At present providing information about patients prognosis by clinicians for patients with cancer, can be inaccurate.The aim of this study is to validate different models of measuring survival in an attempt to improve prognostication in advanced cancer care. This will be done by collecting data from the patient or their next of kin if they do not have capacity. If patients have capacity we will order a blood test. Two clinicians from palliative care involved in their care, will also be asked what they consider to be the patients prognosis.(A Dr & nurse). The patient will be consented & then complete questionnaires at one time point. They will be asked for permission to be followed up by for 12 weeks and to be flagged with the health & Social Care Information Centre (HSCIC) so follow-up can be completed.
The study will run for 2 years.

Inclusion criteria:

  • Patient has been recently referred (or re-referred) to palliative care service. For inpatient palliative care patients, “recent” referral means that the patient should have been first seen by a member of the palliative care team no more than 7-days previously.  For a community, day-hospice or palliative care outpatient, “recent” means that the patient should have had fewer than three previous contacts with the palliative care service before they are recruited to the study.
  • Patients with locally advanced or metastatic, incurable cancer.
  • Aged 18 years or over.
  • Sufficient English language skills for competent patients to understand study literature and undertake study assessments. Whenever possible translation services will be used to maximise the potential for patients or carers to give consent / agreement to participate.

Exclusion criteria:

  • Currently receiving (or planned to receive) potentially curative treatment for cancer.

Contact: Lead Research Delivery Officer: David Kelly, This email address is being protected from spambots. You need JavaScript enabled to view it., Tel: 07900223135